Some preclinical animal studies suggested, however, that GLP-1 analogues and DPP-4 inhibitors may lead to proliferation of pancreatic tissue, including islet β-cells, which raised concerns that they could potentially contribute to the development of pancreatitis and increase the risk of pancreatic cancer. Here, DPP4 is linked to pancreatitis.